Use of osteoporosis drugs in patients with recent-onset rheumatoid arthritis in Finland

H. Hämäläinen, H. Kautiainen, T. Pohjolainen, L. Virta, S. Järvenpää, K. Puolakka

1Rehabilitation Unit, Helsinki University Central Hospital, Finland; 2Unit of Family Practice, Central Finland Central Hospital, Jyväskylä, and Unit of Primary Health Care, Kuopio University Hospital, Finland; 3Rehabilitation Unit, Orton, Finland; 4Social Insurance Institution Research Department, Turku, Finland; 5Medicare Os, Äänekoski, Finland; 6Lappeenranta Central Hospital, Lappeenranta, Finland.

Key words: osteoporosis, rheumatoid arthritis, drugs, register study

ABSTRACT

Objective. We investigated the implementation of pharmaceutical osteoporosis (OP) prevention in early rheumatoid arthritis (RA) in Finland.

Methods. All incident RA cases from 2000 to 2007 were identified using the national register of the Social Insurance Institution (SII) as the sole source. The use of calcium and vitamin D preparations and OP drugs during the first year was evaluated.

Results. A total of 14,878 incident RA patients were found. They had a mean age of 56 (SD 15) and 68% were female. Nine per cent of the total number, which equated to 11% for women and to 5% men, had purchased OP drugs. The use of OP drugs increased over time: in the 2006–2007 period, relative risk (RR) for purchase was 1.62 (95% CI 1.38–1.92) for women and 2.1 (1.34–3.30) for men compared to the 2000–2001 period. Over the 2000–2005 period, 49% of females and 52% of males used glucocorticoids (GCs) during the first year. Among the GC-users, 38% of women and 24% of men also received calcium and vitamin D preparations by prescription, and 14% of women and 6% of men also used OP drugs. For GC users, the female sex, and older age increased the risk for OP use: the respective RRs were 1.45 (95% CI 1.31–1.61), 2.54 (95% CI 2.21–2.91), and 1.060 (95% CI 1.057–1.065).

Conclusion. Patients with early RA are increasingly receiving OP drugs, and the use is more frequent among patients with known risk factors.

Introduction

Rheumatoid arthritis (RA) is one of the well-known risk factors of osteoporosis (OP) (1–4). Inflammation causes bone resorption, which may occur early during the disease course. Periarticular osteopenia is actually one of the American College of Rheumatology 1987 classification criterion for RA (5). Systemic OP in RA is more pronounced in the hip and the radius than in the axial skeleton and is also associated with the severity of RA (6, 7). Glucocorticoids (GCs) are commonly added on to disease-modifying anti-rheumatic drugs (DMARDs) to control inflammation in the treatment of RA (8, 9). Nonetheless, the GCs may aggravate OP, especially in the lumbar spine, though the benefit-risk ratio for this event varies between individual RA patients and also according to the dosage of GCs (5, 10). The fracture risk for patients taking GCs is, however, not exclusively associated with bone mineral density (BMD) (11, 12).

The general risk factors for OP and fractures are present in RA patients, as well (3). Older age increases the prevalence of OP, and half of incident patients with RA are 58 years of age or older in Finland (13). About two-thirds of the patients are women, who at menopause are prone to a major loss of bone mass. Physical activity protects against OP (14). RA patients are less physically active compared to the general population. One of the reasons is the loss of functional capacity (15). Disability as such is a risk factor for OP and also increases risk of falling, which is a major contributor to fractures (16). Active drug treatment limits disease-associated bone loss by several mechanisms (17). Suppression of inflammation restores normal bone turnover, and recovering functional capacity enables physical exercise.

Calcium intake is related, albeit weakly, to BMD (18). Calcium supplementation either alone of in combination with vitamin D reduces the risk of fracture (19). Vitamin D deficiency is prevalent in the general population and among RA patients (20).

Both the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) have published recommendations for the prevention of OP in patients with rheumatic diseases and who receive GC treatment (21, 22). When an RA patient is started on prednisolone ≥7.5mg daily for over three months, calcium and vitamin D supplementation should also be prescribed. Antiresorptive therapy should be considered when fracture risk factors are present.

We evaluated the implementation of these guidelines among Finnish patients with recent-onset RA.

Materials and methods

Finland provides a general health in-
Osteoporosis drugs in RA: a register study / H. Hämäläinen et al.

BRIEF PAPER

Osteoporosis drugs in RA: a register study

Some GC preparations were temporarily excluded from the reimbursement system during the years of 2006 and 2007, which caused some bias. Consequently, we analysed GC use only from 2000 to 2005 inclusive.

Hormone replacement therapy (HRT) was not included, because it is indicated mainly for other reasons than OP per se. The prescription register does not collect data on medications used in hospitals and institutions.

Statistics

Results

We identified 14,878 incident cases of RA from 01.01.2000 to 31.12.2007. Of these, 10,119 (68%) were female and 4,759 (32%) were male. Their mean ages were 57 (SD 14) and 56 (SD 15) years, respectively. Fifty-five per cent of female patients were 55 years of age or older and thus most probably postmenopausal. A total of 1,351 (9%) patients with RA (11% of females and 5% of males) had purchased OP drugs during the first year after commencement of antirheumatic treatment. Women were more prone to using OP medication. Consequently, the age-adjusted relative risk (RR) was 1.45 (95% CI 1.31–1.61), treated with GCs in their first drug treatment year.

The early use of methotrexate medication may be used as a proxy of active RA. Methotrexate was used by 58% of women and by 56% of men during the first year. Patients on OP medication received methotrexate marginally more often (in women 61% and in men 57%, than other DMARDs.

During the period 2000 to 2005 inclusive, about half of the RA patients (49% of females and 52% of males) used GCs in their first drug treatment year. There were no data on the GC dosages, but the common practice in Finland is to prescribe a small dose, usually from 5 to 7.5 mg of prednisolone daily. Of the RA patients that took GCs, 38% of women and 24% of men received concomitant calcium and vitamin D preparations by prescription during the same year, whereas the respective percentages for patients without GCs were 21% and 13%. Of the GS users, 14% of women and 6% of men were prescribed OP drugs. In contrast 8% of females and 3% of males not taking GCs received OP medication.

In the multiple regression analysis, the GC use was determined as a “risk factor” for OP medication: its risk ratio (RR) was 1.45 (95% CI 1.31–1.61), whereas being female had RR of 2.54 (95% CI 2.21–2.91) and higher age had RR of 1.060 (95% CI 1.057–1.065).

Table I. Proportions of initial OP drugs used during the first treatment year by 1351 patients with early RA in Finland from 2000 through 2007.

<table>
<thead>
<tr>
<th>First OP drug</th>
<th>Patients n. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alendronate</td>
<td>803 (59)</td>
</tr>
<tr>
<td>Risedronate</td>
<td>360 (27)</td>
</tr>
<tr>
<td>Etidronate</td>
<td>51 (4)</td>
</tr>
<tr>
<td>Ibudronate</td>
<td>37 (3)</td>
</tr>
<tr>
<td>Clodronate</td>
<td>4 (&lt;1)</td>
</tr>
<tr>
<td>Calcitonin</td>
<td>98 (7)</td>
</tr>
<tr>
<td>Parathyroid hormone analogue</td>
<td>1 (&lt;1)</td>
</tr>
<tr>
<td>Raloxifene</td>
<td>9 (&lt;1)</td>
</tr>
</tbody>
</table>

During the years 2006–2007, 12% of women and 5% of men bought OP medication within 365 days of the index day. The highest proportion was found for the age group 75 to 79 years. Figure 1 shows the use by age-group in 2000–2003 and 2004–2007.

In Finland, preparations that contain calcium and vitamin D, which are also used in OP preventions, are available over the counter so we could not obtain data on their overall use. Many preparations, however, are included in the reimbursement system and reimbursed (42%) to the patient, if purchased to fill a doctor’s prescription. We gathered data on these purchases.

Generally the best RA drugs are prescribed by doctors, but despite good clinical practice, the hospital does not collect data on these purchases.
Discussion

The prevention of osteoporosis and fractures in patients with RA is a recognized issue among rheumatologists, but there is only scant information on the implementation of the published recommendations. To the best of our knowledge, this is the first report that focuses on the use of fracture-preventing drugs in recent-onset RA.

Our study has the advantage of availability of nationwide official register data. Our case definition was based on eligibility for special reimbursement for DMARDs used in the treatment of RA, i.e. a clinical diagnosis of RA by a rheumatologist and the need to initiate antirheumatic medication. No data were available on the fulfilment of the ACR classification criteria for RA, but the use of antirheumatic medication can be regarded as highly indicative for an actual diagnosis of RA. The mean annual incidence of RA from 2000 through 2007 was 44.5 per 100,000 (13), which is congruent with epidemiological data from Nordic countries and the US. Our data comprise the medications that the patients actually bought and, consequently, are more reliable than those based on self-report or patient records. Because calcium and vitamin D preparations are available over the counter, the percentages (42% reimbursement equivalent of 20mg prednisolone (23)) were marked high at the equivalent of 20mg prednisolone (23). Moreover, only 15% of the cohort (18% of women, 9% of men) received anti-resorptive therapy other than HRT.

In a UK study, the general practice records one third of 62,230 women aged 50 and older were sampled (24). Of the sample, 3.2% were prescribed GCs. Mean duration of GC treatment at the time of study was more than 3 years and the cumulative dose was 1.5g per year. About 47% of GC users received either HRT, bisphosphonates, or calcium supplements. The use of HRT was greatest for the age group 50–59 (41%) and became less frequent with older age. At the same time, the percentage of women who received bisphosphonates grew from 8 (50–59 years) to 26 (70–79 years).

Summarising the data from clinical cohorts of established RA with mean durations of several years, the adherence among physicians to OP prevention and treatment guidelines has been poor, nevertheless, some improvement can be seen (25–28). A recent follow-up study suggests, that despite OP drugs, fracture prevention is still a problem (29).

Which incident RA patients who would benefit from medication for fracture prevention actually got the proper prescriptions, is a crucial question. Our results give no accurate answer, because we have no data on disease activity, functional capacity, dose and duration of GC treatment, the general risk factors of OP, and any BMD measurements made. A good proportion of our patients were prescribed calcium and vitamin D supplementation. The use of antiresorptive drugs was more frequent among RA patients with risk factors, i.e. in women, older patients, and those using GCs.

In conclusion, our results suggest that OP prevention among patients with recent-onset RA has become more effective. Further studies on patient cohorts with more detailed data on relevant risk factors are needed to establish, whether the current practices in prevention are sufficient.

References

2. HAUGEBERG G, ØSTRA VIK RE, UHLIG T, FALCH JA, HALSE J, KVIEN T: Bone loss


